This invention relates to a medical management system for automatically monitoring patient medical condition and healthcare provider performance and for promoting prompt timely and immediate patient care in regard to chronic medical patient disease at a reasonable cost.
Diabetic patients test their blood glucose levels at home or at other non-clinical sites using a battery powered, hand-held analyzer and disposable test cells/strips. The patients place a drop of blood onto the test cell or strip and insert it into the analyzer which produces and displays glucose level data. The resultant data, displayed on an LCD contained in the analyzer, indicates the degree of blood glucose control achieved. The patient should use this information to alter his medication, exercise and/or food intake to maintain acceptable blood glucose control. However, this may or may not occur.
Blood glucose data is generally also captured and saved in the analyzer using an on-board memory that can be accessed on the analyzer or downloaded to a PC. This requires special software, along with appropriate cabling and a degree of computer skills. In practice, very few patents use the computer capture of data and even fewer healthcare providers have access to this clinically valuable data.
Healthcare providers, during their routine office visits with the patient, are especially interested in the degree of control the patient has achieved since their last office visit. While there are established testing protocols within the medical community, no record of patient testing compliance is currently readily available to the healthcare provider or relevant managed care organization (MCO). MCOs are the principal organizations paying the costs for analyzers, test cells/strips and diabetes related healthcare costs. Nevertheless, current marketing efforts by manufacturers are virtually exclusively targeted to the patient. In this context, the patient purchases the equipment from the drug store, who then bills the MCO and/or causes the patient to pay. Eventually, then the patient will submit forms and receipts to the MCO for reimbursement.
When the patient goes to a healthcare provider, the healthcare provider may collect a blood sample and then submit the sample to a diagnostic lab. Results of the lab tests are normally not available to the healthcare provider while the patient is at the physician's office. The lab then bills the MCO. The visit to the healthcare provider is also billed to the MCO, either directly, or by paper work requesting reimbursement by the patient.
An article in Medical Technology Fundamentals, February 2001 by Daniel T. Lemaitre et al., Merrill Lynch, pages 259-283, discusses in detail the commercial present situation of diabetes testing and commercial market conditions for various companies in this field. At page 260, the article states that some companies ship test strips automatically to patients without determining the patient's need for supplies and submits to medicare for reimbursement. Insurance companies in many states are required to cover the cost of equipment, strips, monitors etc incurred by patients. Other aspects of this field are also discussed.
US patent publication 2001/0037060 Nov. 1, 2001 discloses a web site for glucose monitoring. The computer system uses glucose data downloaded from the patient's monitor. However, as' noted above, many patients are either computer illiterate or do not want to use such systems. The data is provided back to the user or the users care giver advising adjustment of food, exercise, medications and timed to stabilize glucose levels. Not all patients cooperate with such a system and not all patients even have PCs, especially the elderly and so on. Further, there is no way to insure the monitoring by the healthcare provider or MCO the use of such systems by the patient. These systems require incremental cost to the patient and/or the healthcare provider which further restricts acceptance and usage.
US publication no. 2001/0011224 discloses a modular self-care monitoring system which employs a compact microprocessor-based unit such as a video game system. It includes switches for controlling the device operation and a program cartridge. The cartridge adapts the microprocessor for use with a glucose or other health monitor. The system provides for transmission of signals to a remote clearing house or health care facility via telephone lines or other transmission media. Reports may be sent by facsimile to a health care professional. However, no incentive is provided to insure that the system is put into use and who is responsible for its cost. As a result, such a system is not in use in practice.
US publication no. 2001/0039372 discloses a health monitoring system for communication between at least one terminal device that moves with a person and a first center device. The terminal detects and diagnoses the health of the person and transmits the results to the first center device which stores the historical information and receives the result of the diagnosis and judges whether the detailed data is needed in accordance with the result of the diagnosis. A request command is issued of the detailed data to the terminal device when it judges that the detailed data is needed.
U.S. Pat. No. 6,032,137 discloses a remote image capture with centralized processing and storage. This system is related to credit card receipts and encrypts data, transmit the encrypted data to a central location and transforms the data to a usable form, verifies identification, using signatures and so on.
U.S. Pat. No. 4,731,726 discloses a monitor system which includes means for measuring blood glucose values and for generating glucose data signals. Monitor means is coupled to the measuring means and inputs patient data, means for transmitting and receiving data to and from the monitor means and computing means for receiving glucose data signal in connection with administration treatment for diabetes mellitus. This suffers the disadvantages of the other systems described above.
Health monitoring and reporting systems are also disclosed in US Pats. Nos. 4,803,625; 5,307,263; 5,549,117; 5,704,366; 5,899,855; 6,134,504; 6,168,563; 6,295,506 and 6,290,646 and US Publication no. 2001/0004732.
U.S. Pat. No. 6,270,455 discloses a networked system for interactive communication and remote monitoring of drug delivery.
The problem with all of the above systems is that they do not promote use by the various entities that may use the system and impose incremental cost to the patient and/or healthcare provider and/or MCO. There is no incentive provided to the MCOs, the healthcare providers and the patients to use the systems. Some may require the patients to use computers which is not desirable as explained above. None discuss who is responsible for payment and installation of the system and which entity is responsible for operation of the system in the real world of MCOS, patients and healthcare providers, who are the primary people involved in the network. As discussed above and as shown in the discussion in the Merrill Lynch article cited above, none of these systems are discussed as being practical or being implemented by the primary entities involved in health care management and especially in connection with diabetes.
Diabetes is considered one of the highest cost diseases to treat. This is because the patients require constant monitoring, because if their disease goes out of control, the patient can contract serious complications, such as heart disease, blindness, loss of limbs or extremities, and other serious disabling expansion of the disease to its serious side effects, if not timely treated.
Timely monitoring of the patient is required to show out of control situations, and these out of control situations must be reported immediately to the health care professional, preferably the healthcare provider, as soon as possible. If a patient visits the healthcare providers office and the healthcare provider does not have current information on the patient at the time of visit, the visit is of less significant value. Further, the MCO typically only receives bills from the various providers after the fact. The drug stores bill the MCOs for the equipment and test strips and test cells purchased as well as pharmaceuticals purchased. The healthcare provider also bills the MCO separately. Others involved in providing test strips and monitors to patients may also bill the MCO.
The MCO, however, does not have immediate knowledge of the current condition of the patient. To assist the patient in awareness of the disease, the MCO may send general disease related brochures to the patient with no assurances the patient may read the brochures or if read, take any concrete action based thereon. Further, because patient monitoring is self directed by the patient, the frequency and accuracy of the patient condition is subject to the patient reporting the data to his healthcare provider. Currently, there is no direct means for the MCO, healthcare provider and patient to all be involved in the specific condition of the patient and in ensuring the patient diligently monitors him or herself. While the prior art systems discussed above may alleviate the problem if properly implemented, currently there is no viable approach as to how to ensure such systems in practice are implemented in an industry wide program that is recognized as workable and affordable. As a result, as noted in the Merrill Lynch article, many systems are not presently properly used although they have been available for some time.
The present inventors recognize a need for an apparatus and method that provides incentive to the MCOs, the healthcare providers and the patients to not only implement an interactive monitoring system, but one that will motivate the patient to continue to use the system, that will not only not interfere with the practice of the healthcare provider, but will encourage communication to the healthcare provider, to the patient and to the MCO current status of the disease conditions of the patient and for the MCO to pay the involved costs in a practical manner. None of the prior art systems disclosed above resolve this need. The present invention provides a method for medical management reporting for optimizing patient cooperation with at least a managed care organization (MCO) and optimizing efficiency in providing services in regard to a given disease. The method according to the present invention comprises generating at least an MCO report using a report generating device controlled a CPU which is also communicating with a data base of test data from patients, and transmitting the report to at least the MCO by a communication arrangement. The report manifesting the test analysis of human body fluids of at least one patient, and the report including data manifesting the tested disease status at the time of the test. The report including the time and date stamp for each test and the patient being tested.
A medical management reporting system according to an aspect of the present invention for optimizing patient cooperation with at least a managed care organization (MCO) in regard to a given disease comprises a data base including data received from a plurality of patients via a communication arrangement. The data includes a test analysis of a human body fluid in regard to the current status of a specified disease in each of the plurality of patients at the time of each test periodically conducted by each patient and periodically communicated via the communication arrangement to the database by the patient. A report generating device communicates with the database and generates an MCO report to be provided by an entity. The MCO report including an analysis of the data from the data base manifesting the tested disease status for each test at the time of test, including a time and date stamp for each test and the patient being tested. A communication system is provided for communicating the MCO report to an MCO.
In a further aspect of the system the report generating device is arranged to prepare a healthcare provider report including the same data as the MCO report, and the communication arrangement is arranged to communicate the healthcare provider report to the healthcare provider.
In a further aspect the system includes a central processing unit (CPU) arranged to communicate with the data base, and for operating the report generating device causing the generation of the report.
In a further aspect of the system the disease is diabetes and the body fluid are blood fluids or other bodily fluids manifesting glucose levels in the patient.
In a further aspect the system includes a test unit for generating test data adapted for receiving patient blood or other bodily fluids communicating with the data base for transferring the test data to the database.
In a further aspect of the system the MCO report includes information for specific disease parameter values and the corresponding date of the test creating these values.
In a further aspect of the system the MCO report includes diabetes test data and corresponding date of test including one or more of HbA1c values, glycated protein values, glucose summary data points, hypoglycemic values, and average glucose values over given time periods.
In a further aspect of the system wherein the data base data includes an assigned unique code manifesting the associated patient.
In a further aspect of the system the report generating device is arranged to generate a written report.
In another aspect of the invention a method of medical management reporting for communicating data from a patient to a medical care provider is provided comprising generating a data base communicating with a report generating device. The data base is adapted to receive test data from a plurality of patients each completing a test. The test data pertains to at least one body fluid in regard to current status of a specified disease in each of the patients at the time of each test periodically conducted by the patients. The report generating device generates a report including the data manifesting a tested disease status for each test at the time of the test and communicates the report to an MCO.
In a further aspect the system communicates the report to a health care provider.
In a further aspect of the system the report includes a time and date stamp for each test and information identifying the patient being tested.
In a further aspect the system includes communicating the test data automatically and periodically to the data base, and the test data includes a unique code corresponding to each patient.
In a further aspect of the system the specified disease is diabetes.
In another aspect of the invention a method of medical management reporting for communicating data from a patient to at least one of an MCO and a health care provider comprises providing a plurality of patients with a self test device for generating test data pertaining to at least one body fluid in regard to current status of a specified disease in each of the patients at the time of each test periodically conducted by the patients. The test data is communicated to an entity in regard to the current status of the specified disease. A data base is created at the entity in response to receipt of the communication of the self test generated test data communicated to the entity by the plurality of patients. At least one report is generated from the test data in the data base. The report manifests the test data and analysis of the at least one human body fluid in regard to the current status of a specified disease in each patient at the time of each self test periodically conducted by each patient including a time and date stamp for each self test and the patient being tested. At least one report is communicated to the at least one of or both an MCO and health care provider.
In a further aspect of the system the specified disease is diabetes.
In a further aspect of the system the step of communicating the self test generated data includes communicating the data periodically and automatically to the entity for creating the data base, and the test data includes a unique code corresponding to each patient.
Definitions:
The following terms as used herein are intended to interpreted in view of the following definitions in respect of the following detailed description and in the claims.
1. Managed Care Organization (MCO)— MCO means any organization which oversees the health care of patients and which is primarily responsible for paying the costs of such health care including HMOs (healthcare maintenance organizations), insurance companies, corporations which may or may not have internal health care management plans, medicare, medicaid, or any other entity responsible for payment of the costs of the health care of patients and directly or indirectly responsible for overseeing the health care of patients.
2. Healthcare Provider—The term healthcare provider includes any healthcare professional including physicians, physician assistants, nurses, nurse educators, nurse practitioners, nursing assistants, a hospital providing any of the aforementioned professionals, a clinic providing any of the aforementioned professionals, laboratories, diagnostic facilities and their personnel and so on responsible for the health care or for providing services related to the health care of a patient.
3. Report—As used herein, the term report includes any written or electronic form of data, whether or not displayed, either in raw data form or analyzed as to its significance including charts, graphs, plots, tables or summary information manifesting the significance of the data as applied to a given medical or medical related test.
4. Group of Patients—As used herein a group of patients is any number of patients receiving medical care from a healthcare provider and may include patients grouped by one or more of the patient's healthcare provider, geography, disease, economic status, level of disease control, costs or any other parameter which may provide statistical significant meaning to an MCO.
5. Patient—A person receiving the medical care of a health care provider.
In a first embodiment of the invention, referring to
The entity and CPU generate at least one report via the report generating device 11 for an MCO and communicate the report via the communication arrangement 5 to the MCO. The dashed lines shown in
More specifically, in
The center 3 receives data from the patient test device 10 via a modem 12 coupled to the patient test device 10 or included in the test device. The test device 10 may be a conventional analyzer for use in diabetes analysis, for example, or it may be a unique device developed for such analysis. Generally such analyzers are commercially available as indicated in the various patents noted in the introductory portion. The test device 10,
The patient places the test cell 20,
A preferred device 10 has an LCD display 26 (shown in
The device 10 has a connector 28 which mates with a connector 32 in cradle 30 which receives the device 10. The device 10 includes a modem 34 for communicating with the telephone line 24 or the modem may be in the cradle 30 as may be suitable for a given implementation. The instructions in the program 15 cause the modem to dial up the CPU 4 via the communication arrangement 5 periodically at predetermined times each month, preferably, for example, in the hours after 12 midnight. The patient is instructed to place the device 10 in its cradle 30 each night before retiring. The patient is also instructed to take periodic tests during each day or other prescribed routines. The dial up schedule for connecting the device 10 to the CPU 4 can be changed by the CPU to different hours or to communicate, if desired, more or less frequently, e.g., every week or every day. Thus the program 15 is arranged for two way communication with the CPU for transmitting test data and for receiving instructions for reprogramming the program 15. The program 15 has a code assigned thereto that is unique to that patient assigned the device 10. Each patient has his or her own assigned code.
The patient takes as many tests as prescribed in a given day or days and the data from the analysis of those tests is stored in memory 16 with the time and date of the test. Each test has its associated time and date stamp. The particular analyzed data produced and stored by device 10 is shown in the report of
In
It should be understood, that for other diseases or even in the case of diabetes, the patient may not necessarily be supplied test units in the system 2, which supplying function is optional. Such supplying of test units is preferable, but certain entities may desire other arrangements with respect to the supply of patients with test units, if at all required for a particular implementation.
In
In
As shown in
In an alternative embodiment, the report may be transmitted to the MCO, and/or the healthcare provider, and optionally the patient, or the report may be transmitted simultaneously to the MCO, healthcare provider, and patient. The report to the MCO and healthcare provider transmitted via the communication arrangement which includes transmitting electronically or by mail. Optionally, raw data may be provided the MCO if so desired. The patient report, for example, may be mailed by US Postal Service mail or by access to a secure personal website. In this alternative embodiment, the CPU 4 can compare the patient usage of the test cells 20 with usage and patient inventory. If the inventory is depleted, automatic orders may be generated for shipping replacement test cells directly to the patient according to predetermined quantities as associated with a given patient historical usage pattern.
In
Alternatively, the healthcare provider can be monitored by the MCO as represented by line 66. For example, the MCO can enter the data from the reports 36 from the different healthcare providers in its operations with respect to distribution factors of out of control and in control patients for the disease being monitored. If one healthcare provider exhibits statistical abnormally high out of control patients, then the MCO can take action to discuss this with the healthcare provider The MCO can offer suggestions to the healthcare provider to bring its patients more into control with other healthcare providers in the MCO network by suggesting different protocols etc. in the treatment of the patient. The MCO also can direct specific action brochures and information directly to the patient, or enroll the patient in specific disease management intervention programs to assist the healthcare provider in correcting the out of control condition. Timely action by the patient to correct out of control conditions has a direct correlation in reducing the frequency and severity of serious disease complications. The patient, for example, may be directed to contact his or her healthcare provider immediately or even seek treatment in a hospital emergency room, if necessary. Thus the MCO can initiate intervention programs 68,
In the alternative embodiment discussed above wherein the healthcare provider receives a report transmission, in
The report 36″ sent to the MCO, or any other third-party payor,
A patient report 36,
Thus, the patient preferably uses the blood glucose analyzer and test cell/strips as previously used in prior test systems. The test data is displayed on the analyzer for the patient's immediate action and the data is time and date stamped and stored in the on-board memory 16. This is essentially the same as the system employed by the patient previously.
Each night the patient places the analyzer device 10 in the cradle 30, similar in appearance to chargers used for cellular telephones. The cradle 30 in a preferred embodiment is connected to a communication line 24 such as a telephone line.
The analyzer 14 is programmed to automatically “wake up” at specified and variable times, dial up the host entity CPU 4 and automatically download all time and date stamped data along with the serial number of the analyzer to the CPU. Preferably, the serial number is associated to the patient, the healthcare provider, and relevant MCO, and is automatically so associated by the CPU. During this connect time, the CPU is programmed as needed to communicate with the analyzer and down load such information such as changing the programmed dial up schedule for more or less frequent down load of data, leave alphanumeric messages such as “contact your healthcare provider” or provide early warnings relative to out of control conditions such as excessively high or low blood glucose readings. No patient name is associated with the data and the entity 8 provides privacy for the transmitted medical information. If necessary, this information could also be encrypted.
The entity 8 collects the data communicated via the communication arrangement 5 in the data base 7, analyzes the data at the CPU 4, and prepares computerized reports for the healthcare provider using the report generation device 11, and in an alternative embodiment, prepares report(s) for the patient. The computerized reports highlight the key clinically significant data including all or any of the following but not limited to daily glucose readings, bi-monthly glycated protein levels and quarterly A1c values. Consolidated reports may be prepared and forwarded to the relevant MCO on a periodic basis.
In the embodiment of the system where the patient receives a transmission, it is a benefit for the patient to receive preferably a monthly report. The report may be either hard copy or optionally, by accessing a corresponding secured website maintained by the entity 8 for that patient. This report informs the patient as to how well he or she is keeping the glucose levels under control, alerts the patient to the data that the healthcare provider may optionally have in-hand for the next office visit, identifies the frequency of testing, and provides a reference to the historical glucose control, enabling the patient to note improvements or identify a developing negative trend. When the healthcare provider is transmitted the report, the patient's knowledge that the healthcare provider will have a record of the exact frequency and quantity of testing provides motivation to the patient to better comply with critical testing requirements and glucose control.
In an alternative embodiment, the system provides optional automatic test device monitoring. In this embodiment, the system captures the number of tests consumed by the patient over a specified period and compares that number against the number of tests shipped directly to the patient by the entity 8. This enables the entity 8 to automatically refresh the patients test supplies. No existing test system has this capability. This capability permits the entity 8 to automatically ship product and bill the relevant MCO automatically, for all of the services provided in one bill thereby removing the distribution middleman currently in use by blood glucose manufacturers and MCOs. This results in significant cost savings to the healthcare delivery system and to the MCO in direct costs as well as handling cost for multiple invoices each month.
In another embodiment, the healthcare provider, preferably a physician, receives a single page hard copy report
The ability to incorporate the A1c and glycated protein test results, a capability of an embodiment of the inventive system and method, further enhances the clinical status the healthcare provider is assessing. Since the healthcare provider receives this data prior to the patient visit, patients exhibiting dangerous glucose levels can be contacted immediately to rapidly address the critical situation. This capability does not exist with current glucose systems. The indicated average number of tests performed by the patient enables the healthcare provider to counsel the patient as necessary and promotes greater compliance with the testing protocols. No action is required of the healthcare provider to obtain this information. It is provided automatically on a periodic basis.
The MCO receives periodically, in this example, monthly or any other convenient period, an electronically transmitted report (not shown) consisting of consolidated data custom analyzed per the specific MCOs needs or the same report received by the patient and healthcare provider as may be applicable. A separate report (not shown) identifies those patients within the MCO's plan that are “at risk,” that is, outside the acceptable parameters set by the MCO for its diabetic population. This enables the MCO to target disease management programs to the diabetic population in the greatest need, thereby reducing overall administrative costs. This more effectively utilizes disease management resources and reduces the cost impact of poor outcomes resulting from poor glucose control. This capability is not currently available to the MCO.
Additionally the MCO can monitor healthcare provider compliance with treatment protocols by comparing patient population data. Healthcare providers or healthcare provider groups, that are outside the acceptable standards can be encouraged to improve patient care both by assessing their performance compared to overall MCO healthcare provider population and by direct intervention by the MCO.
In the embodiment of the invention discussed above, the ability to provide test cells directly to the patient population significantly reduces the administrative costs associated with tracking product through the pharmacy distribution chain. Patients that order more tests than are consumed can be readily identified and monitored, a capability not currently available. For example, periodic billing for consumables are consolidated and specific numbers captured to insure appropriate expense payments.
The group placement of patients for providing a third party payee for MCO diabetic subscribers of the MCO is novel and enables MCO control of costs and quality of services. That is, the system 2 permits the MCO to receive reports for all patients who are members of the MCO and who are patients of a given healthcare provider(s), and/or all patients with the same disease, and/or all patients or healthcare providers in a given geographic area and who are members of that MCO, and/or all invoices for common services and goods by cost and other statistical data useful to the MCO for determining out of control treatments or costs for different entities, providers or patient groups who are members of that MCO. This provides a revenue generating transaction between the MCO and the third party entity 8 not hereto before available in prior art systems, which resulted in lack of commercialization of such systems.
While diabetes is disclosed as the preferred embodiment, it is apparent that the disclosed invention is applicable to the control of various different kinds of diseases which may exhibit similar types of control problems as diabetes. By providing a billing system that automatically covers the costs of patient conducted tests to the MCO from the entity providing the reporting service, and enabling the MCO to pay the entity directly for this service, all of the parties benefit without specific costs to each party. The MCO is willing to pay such fees due to significant cost savings afforded by the fact the patient is placed under greater control than provided by present systems and methodology. The MCO pays the report providing entity for the reports, and in the alternative embodiment, the test supplies, and thus is more efficiently operated and minimizes costs to the MCO as incurred in present protocols. MCOs welcome such cost savings while at the same time enhancing disease control which provides even greater potential cost savings to the MCO.
It will occur to those of ordinary skill that various modifications may be made to the disclosed embodiments. The disclosed embodiments are given by way of illustration and not limitation. The scope of the invention is intended to be defined by the appended claims.
This application is a continuation-in-part application of application Ser. No. 10/386,271 filed Mar. 11, 2003.
Number | Date | Country | |
---|---|---|---|
60364710 | Mar 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10386271 | Mar 2003 | US |
Child | 11015860 | Dec 2004 | US |